Kyowa Kirin Co., Ltd.: Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)

CRYSVITA could offer access to the first biologic treatment for EU patients with TIO who cannot undergo surgical removal of tumours Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that

Related Keywords

Japan ,Kyowa ,Hokkaido ,Galashiels ,Scottish Borders ,The ,United Kingdom ,Hamburg ,Germany ,United States ,America ,Great Britain ,Stacey Minton ,Abdul Mullick ,Asia Pacific ,Ralf Oheim ,Hiroki Nakamura ,Kyowa Kirin ,Journal Of The Endocrine Society ,Kyowa Kirin International ,University Medical Center Hamburg ,Nasdaq ,European Union ,Kyowa Kirin Co Ltd ,Committee For Medicinal Products Human Use ,Ultragenyx Pharmaceutical Inc ,European Commission ,Contacts For Kyowa Kirin Co Ltd ,Department Of Osteology ,International Kyowa Kirin ,European Medicines Agency ,Mineral Research ,Tissue International ,Contacts For Kyowa Kirin International ,Medicinal Products ,Human Use ,Tumour Induced Osteomalacia ,X Linked Hypophosphataemia ,Professor Ralf Oheim ,University Medical Center ,Ultragenyx Pharmaceutical ,North America ,Kirin International ,Business Park ,Calcified Tissue ,Tumor Induced Osteomalacia ,Reviews Disease ,Label Trial Assessing Burosumab Efficacy ,Kyowa Kirin Announce ,Kyowa Kirin Announces Approval ,Hypophosphatemic Rickets ,Pirin ,Eceives ,Positive ,Thmp ,Opinion ,Rysvita ,Burosumab ,Treatment ,Humour ,Induced ,Osteomalacia ,